Search results
Showing 466 to 480 of 491 results for %s
Some people with cystic fibrosis are set to benefit from a new once-daily triple therapy treatment, following NICE's recommendation of Alyftrek in final draft guidance published today.
NICE's partners
NICE's past research and projects
NICE responds to publication of the government's Life Sciences Sector Plan
We welcome the publication of the government's Life Sciences Sector Plan, which sets out how NICE will ensure patients get faster, fairer access to transformative new medicines and life-changing healthtech, while supporting a thriving life sciences industry in the UK.
Join NICE's people and communities network
Read NICE's patient and public involvement policy.
To contact us, NICE's website is usually the quickest way to find the answer to a query.
NICE's Freedom of Information Act 2000 provides a right of access to recorded information held by public authorities.
This resource is intended to demonstrate how our guidance can be used in the Care Quality Commission (CQC) assessment process.
NICE's external assessment centre. 1.3 The NICE health technology appraisal(s) of lumacaftor/ivacaftor, tezacaftor/ivacaftor and...
This resource is intended to demonstrate how our guidance can be used in the Care Quality Commission (CQC) assessment process.
This resource is intended to demonstrate how our guidance can be used in the Care Quality Commission (CQC) assessment process.
This resource is intended to demonstrate how our guidance can be used in the Care Quality Commission (CQC) assessment process.
NICE's guidance and advice can help you make the best use of resources and generate cost savings.
NICE leads the way in approving breakthrough treatment for multiple myeloma
People in England will become the first in the world to receive belantamab mafodotin for this indication following our recommendation and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) approval earlier this year.